Nepřihlášený uživatel
You are here: UCT Prague - FFBTDepartment of Biochemistry and Microbiology → Research → Current Projets → Multidrug resistance and post-treatment regeneration
iduzel: 54333
idvazba: 62899
šablona: stranka_ikona
čas: 14.8.2020 03:23:09
verze: 4671
branch: trunk
Obnovit | RAW

Multidrug resistance and post-treatment regeneration

visegrad (originál)

The project is co-financed by the Governments of Czechia, Hungary, Poland and Slovakia through Visegrad Grants from International Visegrad Fund (http://my.visegradfund.org). The mission of the fund is to advance ideas for sustainable regional cooperation in Central Europe. 

Drug resistance plays an increasing role in success of bacterial infections and solid tumors’ treatment. The main limitation to the efficacy of chemotherapy is the multidrug resistant (MDR) phenotype, a multiple resistance towards different anticancer drugs. One of the major mechanism of MDR is the overexpression of transporters that efflux classical chemotherapeutic drugs.

Similar transmembrane efflux pumps are used by bacteria as one of the mechanisms for antibiotic neutralization. These pumps are involved in bacterial resistance to antibiotics (methicillin, chloramphenicol, tetracycline, etc.) or in bacterial intercellular communication that is used to trigger expression of virulence factors, biofilm formation, conjugation, etc.

The search for inhibitors of the efflux pumps can greatly increase the efficacy of conventionally used anticancer drugs and antibiotics. Our aim is to find such substances in plant extracts, fractions and purified compounds or among de novo synthesized or modified compounds using validated methods. For potential compounds that modulate the activity of transporters, further biological activities can be determined, both beneficial (antioxidant, antimicrobial, etc.) and toxic (acute toxicity, genotoxicity, endocrine system impairment, etc.). Only substances with defined biological activities correlating with the concentration range can serve as templates for the design of targeted drugs.

This project is working to improve treatment of patients with MDR tumors and reduce the costs for their management. Second, the project aims at raising the level of Visegrad region research on MDR, reducing the disparity in the research quality, providing the necessary training for Visegrad region early stage researchers (ESRs) to grow as future independent research leaders, regardless of location, age or gender.


vscht (originál)

University of Chemistry and Technology Prague
Technicka 5, Prague, 16628, Czech Republic
coordinator of the project: Dr. Jitka Viktorová

logoUK_side_white_transparent_h95 (originál) Comenius University in Bratislava, Faculty of Medicine
Špitálska 24, Bratislava, 81372, Slovakia
project partner: Dr. Helena Gbelcová
uszeged_logo (šířka 215px)

University of Szeged
Dugonics tér 13, Szeged, HU-6720, Hungary
project partner: Dr. Gabriella Spengler

Updated: 25.5.2020 09:42, Author: Vojtěch Spiwok